Xeris Biopharma Holdings (XERS) Enterprise Value (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Enterprise Value of -$111.8 million for Q1 2026, down 0.64% on a QoQ basis from -$111.0 million in Q4 2025, and down 91.22% year-over-year from -$1.3 billion in Q1 2025.
Xeris Biopharma Holdings (XERS) Enterprise Value (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Enterprise Value history runs 7 years deep, the most recent figure standing at -$111.8 million for Q1 2026.
- Quarterly Enterprise Value fell 91.22% year-over-year to -$111.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$111.8 million (down 91.22% YoY) and the FY2025 annual result came in at -$111.0 million, down 55.04% from the prior year.
- Enterprise Value was -$111.8 million for Q1 2026 at Xeris Biopharma Holdings, down from -$111.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$58.4 million in Q1 2025 and bottomed at -$132.1 million in Q1 2022.
- A 5-year average of -$88.9 million and a median of -$87.4 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value surged 40.6% — and 2026, when it slumped 91.22%.
- Xeris Biopharma Holdings' Enterprise Value stood at -$122.0 million in 2022, then jumped by 40.6% to -$72.5 million in 2023, then advanced by 1.15% to -$71.6 million in 2024, then tumbled by 55.04% to -$111.0 million in 2025, then dropped by 0.64% to -$111.8 million in 2026.
- Business Quant data shows XERS's Enterprise Value at -$111.8 million in Q1 2026, -$111.0 million in Q4 2025, and -$91.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | -1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -4.05 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -2.15 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -1.32 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -428.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | -111.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -111.75 Mn |
| Dec 31, 2025 | -111.04 Mn |
| Sep 30, 2025 | -91.60 Mn |
| Jun 30, 2025 | -59.29 Mn |
| Mar 31, 2025 | -58.44 Mn |
| Dec 31, 2024 | -71.62 Mn |
| Sep 30, 2024 | -69.40 Mn |
| Jun 30, 2024 | -77.57 Mn |
| Mar 31, 2024 | -87.35 Mn |
| Dec 31, 2023 | -72.45 Mn |
| Sep 30, 2023 | -65.98 Mn |
| Jun 30, 2023 | -80.67 Mn |
| Mar 31, 2023 | -95.10 Mn |
| Dec 31, 2022 | -121.97 Mn |
| Sep 30, 2022 | -93.43 Mn |
| Jun 30, 2022 | -111.55 Mn |
| Mar 31, 2022 | -132.15 Mn |
| Dec 31, 2021 | -102.43 Mn |
| Sep 30, 2021 | -92.98 Mn |
| Dec 31, 2020 | -133.79 Mn |